TETRA-HD - The U.S. Food and Drug Administration today (August 15, 2008) approved tetrabenazine, the first drug approved for use in the United States to treat Huntington’s disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease (read more...). Prestwick, the TETRA-HD study sponsor, has posted information on their web site; HDSA has posted an article by Marsha Miller, PhD on their web site.

The 2CARE trial is now enrolling. (read more...)

COHORT has enrolled over 1,400 study participants to date. (read more...)

The DIMOND study sponsor, Medivation, made a public announcement about the top-line study results on July 7, 2008. Please see the Medivation Press Release, and also the Commentary by Marsha Miller for more information.

The Second Annual Huntington Disease Clinical Research Symposium (HDCRS) is now accepting online registrations and late-breaking research abstract submissions. See 2008 HDCRS for more information.

Our HSG web site is newly-remodeled as of July 2008. Please send us an email and tell us what you think. Thank you.

The Huntington Study Group participated as an exhibitor at the June 2008 HDSA Convention in Pittsburgh. The exhibit booth handouts are now available.